Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.
Roger von Moos(Kantonsspital Graubünden), Kathrin Zaugg(Ontario Institute for Cancer Research), Ludwig Plaßwilm(University of St. Gallen), Daniela Baertschi(Swiss Group For Clinical Cancer Research), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Piercarlo Saletti(Institute of Oncology Research), Dirk Klingbiel(Max Planck Society), Martin D. Berger(University of Bern), Paola Izzo(University of Naples Federico II), P Thum, Urs R. Meier(Kantonsspital Winterthur), Dieter Koeberle(Kantonsspital St. Gallen), Pu Yan(University Hospital Zurich), Ralph C. Winterhalder(Luzerner Kantonsspital), Panagiotis Samaras(University Hospital of Zurich), Arnaud Roth(Hôpital Beau-Séjour), Daniel Rauch(Washington University in St. Louis), Sabina Schacher(Kantonsspital Winterthur), G. Bodoky(Unified Szent István and Szent László Hospital)
Cited by 5
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k